title: [Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].
abstract: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in non-small cell lung cancer (NSCLC) patients, it is still controversial about how to combine EGFR-TKI with chemotherapy and other targeted drugs. We have made a summary on the current therapeutic models of EGFR-TKI combined with chemotherapy/bevacizumab in this review and aimed to find the optimal therapeutic strategy for NSCLC patients with EGFR mutation.
authors: Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou 310027, China.
authors: Zhong
authors: Z
authors: Shi
authors: Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou 310027, China.
authors: Yun
authors: Y
authors: Fan
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D009154:Mutation
chemical_list: D004791:Enzyme Inhibitors; D066246:ErbB Receptors